Cholesterol - A Review
by William R. Ware, PhD
Coronary angiography involves inserting a catheter into the femoral artery in the groin and pushing it up through the aorta until it reaches the coronary vessels. A contrast medium is then injected to allow imaging of the individual coronary arteries and these images can reveal blockage attributed to atherosclerosis. Thus studies can examine the correlation between serum cholesterol and angiographically identified deposits and narrowing in the coronary arteries. But coronary angiography is not without its morbidity and mortality and is generally performed only on individuals with at very high risk or with severe symptoms of heart disease who are young or middle-aged. Thus these studies are not representative of the asymptomatic public. In addition there will be some patients who have familial hypercholesterolemia. This would introduce a bias since, as will be discussed below, it is not at all clear that the atherosclerosis that accompanies this syndrome can be compared to that found in individuals who do not have the mutation. Any study heavily weighted with individuals having very high cholesterol levels will be confounded by the potential presence of subjects with this syndrome. Also, in many studies, cholesterol lowering drugs were being used, further confusing the question.
Thus if the issue is the Cholesterol Hypothesis, angiographic results do not appear to be a very good way to study its validity. On the other hand, both the autopsy and calcium score approaches allow the examination of asymptomatic individuals which is much more to the point and less subject to confounding and bias. Nevertheless, as Ravnskov  discusses at length, angiographic studies that examined the relationship between cholesterol levels, their changes, and the presence and progression of atherosclerosis frequently found inconsistent results where progression occurred in the presence of both increasing and decreasing cholesterol levels. In his words, "to prove that high cholesterol is the villain - not just an innocent bystander - demands that a change in the cholesterol concentration for each individual is followed by a change in the degree of atherosclerosis in the same direction. But in all studies these changes occurred haphazardly." Also, most of the results are presented as the constants of correlation equations and almost always the degree of correlation is very poor (low correlation coefficient).
HOW ABOUT FAMILIAL HYPERCHOLESTEROLEMIA (FH)?
An interesting and perhaps unique study from the Netherlands relates to this question. A large pedigree was traced back to a single pair of ancestors in the 19th century and a family tree mortality study conducted which started in the early 1800s. All members had a 50-50 chance of carrying the mutation for familial hypercholesterolemia. Mortality data over the full time span up to modern times was available for this large group as well as for the corresponding general population. Overall mortality was not increased in carriers of the mutation during the 19th and early 20th century. The mortality then rose reaching a maximum between 1935 and 1964. The authors comment that the risk of death varied significantly among patients with FH and that this was, in their opinion an indication of strong interaction with environmental factors. One can of course ask why for over more than a century no excess mortality showed up because of the elevated TC and LDL levels if in fact these lipoproteins cause atherosclerosis and CHD.
Kendrick  suggests that perhaps lipoprotein (a) is involved since there seems little doubt that this protein is elevated in those with the FH mutation and that this protein is regarded as a strong independent risk factor for CHD. However, he finds the strongest argument against FH causing CHD is that most people who die with heart disease do not have highly elevated LDL levels and most who have these LDL levels do not die of heart disease, even people with FH.
THE MONICA STUDY
Japan merits a bit of discussion. The Japanese living in Japan in general had both low cholesterol levels and low rates CHD mortality, but immigrants to the U.S. had high cholesterol levels and had CHD mortality comparable to Americans. Convincing proof of the Cholesterol Hypothesis. But let's dig deeper and look at what a British physician found during his Ph.D. research. He looked at the relationship between TC levels and social factors, eating habits and lifestyle among the immigrant Japanese. He found conclusive evidence that it was not the food that raised the cholesterol of the Japanese immigrants, or that elevated cholesterol values increased their risk of CHD death. Rather, he found that those who maintained their cultural traditions were protected against heart attacks, even though their cholesterol increased as much as in the immigrants who adopted the Western lifestyle and diet and who died from CHD at a rate comparable to the Americans. In fact, the Japanese who preferred lean Japanese food but adopted other aspects of the American way of life had CHD twice as often as those who maintained Japanese traditions but preferred standard American diet [20,21]. These studies, which contradict the Cholesterol Hypothesis, have been largely ignored, in spite of having been published in a high profile peer-reviewed American journal. Thus, if the low rate of CHD among the Japanese has little to do with cholesterol levels and the low mortality is for other reasons, then the MONICA result for Japan are explained. This leaves only one discordant point in an otherwise apparently random scatter of points in the Monica results.
The relationship between cholesterol levels and mortality is actually both complex and fascinating and will the subject of Part II of this review.
FRAMINGHAM RISK SCORES
The Framingham study also gave rise to the so-called Framingham Risk Score, a risk estimate of having CHD during the next 10 years. This score is widely used in the office setting to assess an individual's risk of CHD. If one looks at the way the score is calculated, as one gets older, age become by far the dominant factor with the importance of cholesterol dropping off dramatically with age until it becomes almost insignificant for men and makes only a slight contribution for women. This is in spite of the arterial exposure to TC and LDL obviously increases with age. This is not a picture of overwhelming support for the Hypothesis.
WHAT ARE THE REAL RISK FACTORS FOR ATHEROSCLEROSIS?
Mainstream medicine regards the cholesterol-heart disease connection as an established fact. It has been elevated almost to a sacred belief. Anyone who questions the foundations of this hypothesis runs the risk of being branded a heretic or someone who is unable to appreciate the wisdom and beauty of one of medical science's outstanding achievements. Many careers have been built on the Cholesterol Hypothesis, careers replete with high profile medical academic positions, drug company supported lectureships and consulting and financial support for research. Any medical professional who openly expresses serious doubts runs the risk of being ostracized by his or her peers. But there are indeed deniers and sceptics, and it seems important that Newsletter readers are aware of their views [1,2]. Avid readers of the British journals The Lancet, the Quarterly Journal of Medicine and the British Journal of Medicine are probably among those most keenly aware of these voices crying in the wilderness. Such criticism or questioning is rare in North American Journals. But science thrives and progresses on dissent, controversy and attempts to falsify hypotheses, a fact that seems underappreciated by those who guard the conventional wisdom. Some would argue that this does a profound disservice to the progress of medical science and the ultimate discovery of so-called truth.
Painting cholesterol and in particular LDL as demons, sort of on a par with toxic substances or even pathogenic bacteria, is unfortunate since this almost totally obscures the fact that cholesterol is essential for our wellbeing. It is involved in ensuring the integrity of cell walls and in the synthesis of testosterone, estrogen, dehydroepiandrosterone (DHEA), progesterone, cortisol, and last but not least, vitamin D by photosynthesis from the exposure to skin to ultraviolet light. We produce cholesterol in the liver, and in general, high dietary consumption results in lower endogenous production, and many feeding studies have found virtually no dependence of serum levels on dietary intake . This is obviously inconsistent with the conventional wisdom which suggests limiting the dietary intake of cholesterol, a recommendation which the food industry picked up on and has played to the limit. Finally, the Cholesterol Hypothesis has resulted in widespread screening and a vast amount of anxiety, stress and pharmaceutical intervention over cholesterol levels labeled elevated and declared dangerous and even life-threatening.
What we will call the Cholesterol Hypothesis simply states that that high levels of total cholesterol, i.e. TC and LDL cholesterol (LDL), cause atherosclerosis and are associated with elevated risk of developing coronary heart disease. The word cause is important in this context because cause is relatively difficult to establish in many human disorders and CHD appears to be one of them. The reason in part is the extraordinary complexity of the sequence of events associated both with the development of atherosclerosis and the events leading to an acute coronary episode, e.g. a heart attack. One thing that appears clear is that the simplistic view of cholesterol clogging up ones arteries (the kitchen drain analogy) is just that - simplistic. The evidence against the Cholesterol Hypotheses as regards cholesterol-causing atherosclerosis was reviewed in Part I.
STUDIES CONCERNING CHOLESTEROL AND MORTALITY
One of the largest and most recent studies to address the mortality issue was published in 2004 and involved almost 150,000 Austrian men and women ages 20 to 95 years . The study involved multiple evaluations of total cholesterol over a 15-year period between 1985 and 1999. Overall (all-cause) mortality and CHD mortality were evaluated by comparing the lowest and highest quartiles of TC with the middle quartiles used as reference. The following results are of particular interest.
Thus for overall mortality, high TC was not a significant issue for men over 50 or for women at any age, but in fact there was evidence of increased overall mortality associated with low cholesterol. For men under 50 years of age, overall mortality exhibited a U-shaped curve vs. TC. For women, the mortality rate curve which has been seen in many studies is more or less flat at high to intermediate TC levels and then slopes upward indicating increased mortality associated with low TC.
The weak positive association between CHD mortality and high TC for men over 65 is inconsistent with a large number of earlier studies. Ravnskov has summarized these studies in a recent commentary . His review summarized 13 studies, the largest 4 of which involved over 12,000 men and women, where 7 studies found that the lower the TC or LDL, the higher the mortality, and all 13 studies found that high TC or LDL did not predict increased mortality in this age group. Seven of these studies had subjects in the age group 60-65 years and one exhibited an inverse relationship where increasing TC decreased coronary mortality (this was actually part of the famous Framingham Study).
Similar results related to elderly men were reported for the Honolulu Heart Program follow-up study which involved over 3500 men followed for a maximum of 20 years . The age range was 71-93 years. Mean cholesterol levels for the quartiles were 149, 178, 199, and 231 mg/dL. When the lowest quartile for TC was used as reference, the relative risk for all-cause mortality decreased (0.72, 0.60 and 0.65) as TC levels increased. Thus there was benefit rather than risk associated with high TC as it relates to all-cause mortality. When results from the first year of follow-up were excluded, similar risk reduction with increasing TC were found. This argues against the low levels being due to preexisting illness. In addition, the long-term follow-up in this study, in the opinion of the authors, renders the hypothesis untenable that the low TC effect is due to undiagnosed preexisting conditions that reduced TC levels. The authors state that, "We have been unable to explain our results." This could be translated into a statement that the results are not in accord with the conventional wisdom.
In a U.S. study involving over 10,000 men and 8600 women, the relationship between TC and all- cause mortality was determined over a follow-up period of 22 years . There was no stratification by age. For women, there was no significant association with overall mortality and TC. A third of the women had TC < 201 mg/dL and a third had TC > 240 mg/dL. For men, the only positive association was for TC > 240 mg/mL, but the relative risk was the lowest among all the risk factors that gave a positive association (e.g. blood pressure and smoking).
In a large study of Korean men aged 30-65, it was found in a 6.4 year follow-up a low cholesterol level (< 165 mg/dL) was associated with increased risk of all-cause mortality . The risk of CHD mortality was found only for men with the highest cholesterol levels (greater than equal to 252) but there was no stratification by age. Thus this study also found a U-shaped relationship between overall mortality and TC. The strongest disease specific increase in mortality with decreasing TC levels was seen for cancer. The authors rule out the possibility that this was due to preexisting cancer since attempts were made to exclude patients with cancer or precancerous condition at baseline, and the increased risk of cancer with decreasing cholesterol levels remained significant throughout the 5-year follow-up period. This is an important point since the conventional explanation offered by mainstream medicine for the increased cancer mortality with decreasing cholesterol levels is that it is due to a preexisting condition that resulted in the low level. Also, the absence of increased cancer incidence in studies where cholesterol was aggressively lowered with statins in studies for secondary prevention or with very high risk individuals does not appear relevant to the above issue since the patient population was different and there is the possibility that the statin drugs have anti-cancer properties unrelated to cholesterol lowering.
Studies published very recently present the same picture. Mortality was significantly correlated only with a low level of TC (less than equal to 160 mg/dL) in a small group of men and women 84 years or older . In as study of over 300,000 Korean women age 40-64, no significant association was found with TC and CHD mortality for the 40-55 age group of pre- or postmenopausal women. For the 56-64 age group, the only significant association was for TC levels greater than equal to 236 mg/dL, i.e. the highest quartile. Given that all other associations were non-significant, this single result may be a fluctuation . Finally, in a study of individuals presenting with ischemic stroke (from a blood clot) it was found that higher cholesterol levels favored minor strokes and thus post stroke mortality was inversely related to cholesterol 
Stamler et al examined the question of the relationship between TC and all-cause mortality and CHD mortality by an analysis of three prospective studies involving men 39 years or less of age . One study had a mean age of about 30, another 32 the third study 37 years. In men in this age group, the overall and CHD mortality risk was elevated when those with elevated TC levels were compared to those with TC < 160 mg/dL but in the largest of the three studies which involved over 60,000 participants, significant increased in all-cause mortality was seen only for levels above 230 mg/dL when TC was stratified into quintiles. The two other studies revealed CHD mortality risks in all quintiles above the reference quintile (< 160 mg/dL). These results are consistent with studies discussed above where the data was stratified by age. The authors conclude that these results suggest a longer life expectancy for younger men with favorable cholesterol levels.
Thus there appears to be little data to indicate that elevated cholesterol levels are positively associated with CHD or overall mortality and in fact the opposite appears fairly well established, low cholesterol levels are accompanied by elevated mortality. Young men appear to be an exception.
CHOLESTEROL AND SUDDEN CARDIAC DEATH
Thus the picture emerges that if cholesterol levels are considered in the context of overall or CHD mortality high cholesterol is only an issue for young men and appears protective for women of all ages and men over 50 years of age. However, this applies to individuals who do not have coronary heart disease.
The current guidelines  of the National Cholesterol Education Program for TC (mg/dL) are:
It seems noteworthy that these guidelines are not stratified by either age or gender. While the guidelines emphasize LDL, to a large extent TC is a surrogate for LDL in that high TC almost always implies high LDL. The guidelines also focus on risk of CHD rather than mortality, but the issue being discussed here is in fact mortality and whether or not serum cholesterol levels are related to either CHD mortality or all-cause mortality. However, the guidelines do introduce age and gender, but only when the estimation of risk is with the Framingham risk factor calculator. In one version of the Framingham data, risk for CHD includes fatal or non-fatal heart attack and unstable angina. In another version fatal and non-fatal heart attacks are the only endpoints.
HOW ABOUT THE ENHANCED RISK OF CHD IN YOUNG MEN WITH ELEVATED TC?
It seems obvious the there is an anomaly associated with young men and the risk of CHD mortality associated with elevated TC. Why for example, does the risk not persist in older individuals where the exposure to circulating cholesterol is much longer? It does indeed appear to be true - high cholesterol predicts CHD in young and middle-aged men. But if cholesterol is merely a marker and plays no role in causative mechanisms, then the problem posed by young men can be resolved if some mechanisms unique to this age and gender group are responsible for cholesterol elevation. It has been suggested  that one factor may be stress which is well known to elevate serum cholesterol levels, and which would be expected to peak in age period prior to 50. Ravnskov  suggests a number of factors which can be expanded upon. This is the age where most men are in the midst of their professional careers, in many cases subject to great stress, even harassment. After all, it is well known that many individuals hate their jobs, their boss, the part of the country where they work, etc. There is the ever present risk of being fired, making mistakes that lead to bankruptcy, loosing ones job because of downsizing or failing to achieve or get promoted or get that much desired executive position, etc., etc., etc. There is the worry of loosing ones job at an age where it would prove difficult if not impossible to get an equivalent one. This is the age where marital break-ups are common and are generally highly stressful, where teenage children drive their parents mad or frantic with worry. It is when ones children may succumb to drugs and alcohol, and the age where parents sometimes have to contend with a child's unwanted pregnancy. One could go on indefinitely with the potential horrors that might confront the middle age man.
There have been a number of studies that examined the association between cholesterol levels and work-related stress. While it is true that the higher the stress the higher the serum levels, the magnitude of elevation is small and does not seem sufficient to support the idea that this is the mechanism giving rise to the anomalous effects seen in young men, which incidentally includes a weak but significant correlation between CHD in general and TC. Thus there is a problem with Ravnskov's suggestion. However, studies of cholesterol and CHD events or mortality that correct for confounding have of necessity failed to take into account at all one confounder, the magnitude of blood pressure changes due to stress. If resting blood pressure is measured and used as a variable in adjusting the association between CAD and cholesterol, this ignores the fact that higher levels of cholesterol appear to be associated with enhanced or exaggerated response to stress (hyper-response) and hyper-responders have enhanced CHD risk in response to stress. Thus in the population of young men, there will be these hyper-responders who will on average have considerably higher cholesterol levels, but it is the hyper-response of blood pressure to stress that increases the risk and thus the action of cholesterol is indirect. The impact of large fluctuations in blood pressure occurring on a daily basis in response to stress, either work related or domestic, would be the direct but unmeasured association with increased risk of CHD mortality or events. This could account for the modest correlations between CHD mortality or CHD events and cholesterol in young men who are exposed to a higher level of stress than older men and who may cope with stress less successfully than women. If studies had adjusted for the magnitude of blood pressure response to stress challenges it is suggested that the modest connection between cholesterol and CHD risk might disappear . But operationally this appears impossible in studies large enough to provide adequate statistics since all that is practical to measure is resting blood pressure and it is obviously impossible to duplicate in a clinical examination or screening session the day- to-day stress of a toxic workplace or the stress associated with domestic problems.
In his recent book The Myth of Cholesterol, Dr Paul Dugliss, M.D. makes a case for stress being so important in the etiology of CHD that it renders cholesterol to a position of near irrelevance. He compares typical estimates of risk reduction due to stress reduction with risk reduction from cholesterol lowering drugs. The former can result in risk reductions of up to 540% for heart attacks, whereas typical risk reduction with lipid lowering is about 25% (but only in the subgroups where it works at all).
This view is strongly supported by results from the INTERHEART study, a case-control study involving subjects from 52 countries that examined the relative importance of risk factors for heart attacks . It was found that psychosocial factors including stress at work and at home, general and financial stress, stressful life events, and depression resulted in risk of heart attack that was greater than diabetes or smoking, both of which are major traditional risk factors. Diabetes alone automatically confers a 10-year risk of CHD or CHD events of greater than 20%, i.e. high risk.
HOW ABOUT HDL, THE SO-CALLED GOOD CHOLESTEROL?
A study from Finland  looked at CHD mortality and HDL. The variation of HDL levels with age over the total range from 25 to 64 was very small and thus the results without age stratification are of interest. For both men and women, the risk reduction for CHD mortality was about 10% per 4-mg/dL increase in HDL and was statistically significant. This appears to be clinically relevant since the difference between high and low HDL is about 20 mg/dL.
In a study of type 2 diabetics, cardiovascular mortality rates were independent of TC or LDL but significant protection was seen with HDL levels greater than about 53 mg/dL. The follow-up involved over 10,000 person-years and age did not influence the protective effect of HDL. However, adjustment for a large number of potential confounders reduced the benefit in all but those >70 years of age . Thus there is nothing in these studies which contradicts the belief that high levels of HDL are protective.
It is also noteworthy that the vast majority of acute coronary events such as heart attacks occur after the age of 60, an age where the question of cholesterol and either CHD mortality or overall mortality becomes an issue only in that high TC appears either neutral or decreases rather than increases the risk of death. Thus, for a large fraction of the adult population, concern about high cholesterol amounts to worrying about something that appears to have no bearing on CHD mortality, and perhaps even increase life expectancy.
There are millions of individuals taking cholesterol-lowering drugs. The number worrying about their high cholesterol must be very large indeed. The total drug company income from statins is approximately $55 billion (not a misprint) per year. Today, recommendations are mainly based on LDL cholesterol, medical history and the presence of traditional risk factors, two of which (Framingham) depend on TC and HDL. But levels of LDL are closely tied to TC. Thus the studies that examined mortality as a function of TC are relevant. The evidence or lack thereof presented above would suggest that the recommendation of these drugs for women and the elderly who are free from symptomatic CHD and have not had a heart attack is not based on evidence involving risk of either CHD mortality or all-cause mortality, and some regard this as the most important consideration. If low TC indeed increases mortality, then this becomes an additional consideration, one that probably never comes up in consultations since mainstream medicine dismisses all the data regarding this problem with arguments given above. In addition, in younger men, high TC may lead to inappropriate therapy if the real problem has to do with high stress. Also, obsession with cholesterol levels may result in avoiding a number of potential actions associated with primary prevention. Since statin drugs have side effects, the above considerations assume added significance.
Thus we have now seen in the first two parts of this series that there does not appear to be a connection between CHD mortality or all cause mortality and circulating cholesterol. Nor are cholesterol levels associated with the extent of atherosclerosis. In connection with this second point, the British physician Malcolm Kendrick, a long-time student of the Cholesterol problem, poses three key questions in his book The Great Cholesterol Con:
When one thinks about it, it is remarkable that atherosclerosis does not develop in veins. They have the same cellular wall structure as arteries and they are exposed to identical levels of TC and LDL. If an artery is replaced by a vein, as in bypass surgery, the vein now acting as an artery can develop atherosclerosis as frequently seen in bypass restenosis, but replace a vein with an artery and the artery appears protected against atherosclerosis. Kendrick concludes that this has something to do either the position in the body or the function of arteries. But how can LDL be the culprit since it remains constant throughout the circulatory system?
For the discrete plaque patch puzzle, he likens this to sunbathing and getting burned only in patches in spite of uniform exposure, the analogy being with the uniform exposure to the hypothetical causative agent cholesterol. If plaques form in damaged areas and LDL does not itself damage the arterial walls, then something else causes heart disease.
Defenders of the Hypotheses respond to the third question by simply saying the low LDL levels that still result in atherosclerosis are not really low but are in fact high, and that almost everyone has the disease of hypercholesterolemia and clearly need aggressive therapy. Mankind has evolved, perhaps even over the past century, such that they now have a deficiency disease, where the deficiency is a prescription drug. Critics tend to view this explanation as total nonsense. This view will be examined and documented in Part III of this series.
A simple solution to the problems posed by these three questions is that the Cholesterol
Hypothesis is false.
STROKE RISK AND CHOLESTEROL
Two studies were not considered by Law et al, in one case simply because the study came after their paper was prepared. One, the Eurostroke Study, which examined both ischemic and hemorrhagic strokes in the general population using a case-control model, found no significant association between cholesterol and either stroke type, fatal or non-fatal . A very large prospective Korean study reported in 2006 . Involved were over 787,000 individuals which provided a large number of strokes for analysis. Six ranges of total cholesterol were used, with < 130 mg/dL as a reference. When the results were adjusted for confounding, only cholesterol levels grater than 270 mg/dL were associated with increased risk of ischemic stroke, and only 0.9% of the subjects were in this category. For everyone else, there was no statistically significant association. For hemorrhagic stroke, total cholesterol levels above 160 mg/dL were protective when < 130 mg/dL was used as the reference, i.e. as cholesterol levels increased, the risk decreased. However, an interesting connection with alcohol consumption was made. By using a blood marker for alcohol consumption, it was found that when this marker was low, the association between low cholesterol and enhanced risk of hemorrhagic stroke disappeared. Thus in apparently healthy populations, the balance of evidence suggests that the incidence of stroke is unrelated to serum cholesterol levels but someone with a very high level may be at a modestly enhanced risk.
The absence of an association between cholesterol levels and the risk of ischemic stroke was termed a paradox by Matthias Enders in a review published in 2005 . But he points to an additional paradox. Given that cholesterol does not appear associated with the incidence of ischemic stroke, it is then curious that treatment with statin drugs reduces the incidence of stroke, at least in patients with existing CHD or a history of stroke. Several studies have shown this. When data was combined from 9 trials including over 70,000 participants with established CHD or high risk of CHD, the relative risk reduction was 21% with an absolute risk reduction of 0.9% (number of individuals needed to treat to prevent one stroke--111) . When intensive (higher dose) statin therapy was compared with therapy using usual doses, a pooled analysis of 4 trials yielded an additional 18% relative risk reduction but only a 1/2% absolute risk reduction . In older studies statins were not found to reduce stroke risk in typical populations without known CHD, but in these primary prevention studies the age was rather low and thus so was the stroke incidence, and these trials lacked the statistical power to reliably detect a significant effect. For asymptomatic individuals not deemed high-risk, the benefits of statins for primary prevention is not clear. But there remains the problem of whether or not the primary action of the statin drug in this context is related to cholesterol lowering or some other anti-stroke action. Enders points out that the observed dose dependence relative to baseline cholesterol levels suggests that cholesterol lowering may not be the important factor, and this view is bolstered by studies of cholesterol lowering using non-statin drugs where there was no decrease in stroke incidence in spite of significant cholesterol lowering .
There is some evidence that low cholesterol levels induced by statins increase the risk of hemorrhagic strokes [9-12]. In the just published SPARCL trial it was found that treating 1000 ischemic stroke and transient ischemic attack patient with high-dose atorvastatin for over one year will avert 4.8 ischemic strokes while causing 1.9 additional hemorrhagic strokes [11,12]. It is also interesting that post-stroke mortality is inversely related to cholesterol levels because higher cholesterol levels are associated with less severe strokes . Finally, in a study of diabetics, while statin treatment reduced non-hemorrhagic strokes by 50%, the benefit was independent of baseline cholesterol and the presence or absence of a first stroke .
Taken together, all this evidence strongly suggests that the benefits of statins in the context of stroke has little to do with cholesterol lowering and may be due to other actions of these drugs.
LIPID LOWERING TRIALS
Some lipid lowering trials were exclusively for primary prevention, some only for subjects with CHD, and some looked at both. There have been trials that exclusively enrolled men and those that had a mix of genders. In several studies, women have been seriously underrepresented. A number of different statins have been tested.
For primary prevention using statins the available studies are very limited. One is 100% male and the other two are 82-85% male. One  recruited only hypertensive individuals with at least three other CVD risk factors (ASCOT), and one  had a lower limit on baseline TC of 252 and a mean of 272 mg/dL, which translates into a significant percentage of individuals with family related high cholesterol (FH) (WOSCOPS). The one that came closest to reflecting characteristics of the general population was AFCAPS  where the mean TC was 221 and LDL ranged from 131 to 191, although this cohort had low HDL. Here are the results:
A meta-analysis of seven primary prevention randomized controlled trials involving statins was published in 2006 which included the above three studies . The results were as follows:
|Major CHD events||
No significant effect of statin treatment on coronary heart disease mortality or overall mortality was found. For individuals in the Framingham low or intermediate risk categories, statin therapy was estimated to reduce the absolute risk of major coronary events by 0.75% and 1.63% respectively. Thus this analysis which involved almost 43,000 participants overall provides a similar picture to that for the three studies discussed in detail above. The absolute risk reduction is just slightly above negligible. However, from the public health point of view, even these small reductions would add up to a large number of events prevented in a large population such as the US, The benefit found for Framingham high-risk individuals was greater with a 2.51% absolute risk reduction, but the use of statins in this group is less contentious than for the low and intermediate risk groups.
It is not clear the extent to which these results apply to women since they were severely underrepresented. Also, the ASCOT trial does not apply to the general population, only a hypertensive population at high risk of CHD. Critics of the Cholesterol Hypothesis consider the small absolute risk reduction to be inconsistent with cholesterol being regarded as a large, significant and highly important risk factor. Believers say the above studies prove that serum cholesterol and in particular LDL actually causes atherosclerosis and CHD and in addition, lowering TC or LDL by 20-30% reduces CHD events by 20-30%. As discussed below, when the primary prevention studies are stratified for women of all ages and the elderly, the risk reduction of statin treatment disappears leaving only young men as beneficiaries, and some would regard number of young men needed to treat of 50-70 to prevent one adverse event as suggestive of marginal benefit. Treatment is generally for life.
Most of the research in lipid lowering has centered on secondary prevention and the comparison between low and high dose protocols. Regarding the former, Costa et al have provided a meta- analysis of 7 studies . The result was as 23% reduction in major coronary events and the absolute risk reduction was 5.1% with the NNT about 20. In the meta-analysis discussed above , for trials where secondary prevention was also involved, the relative risk reduction for major coronary events was 20.8% with an absolute reduction of 2.4% and the number needed to treat of 33. In this study of secondary prevention trials there was also no statistical significant association between statin treatment and coronary heart disease mortality or overall mortality.
Studies aimed at evaluating the benefits of high-dose statins vs. the usual dose have examined either individuals with stable CHD or those experiencing an acute coronary syndrome. Cannon et al have performed a pooled analysis of 4 studies . When the two dose protocols were compared, the reduction in risk of CHD mortality or heart attacks achieved for high dose statins was 16% with an absolute risk reduction of 1.4% and the NNT was 71. The benefits should be viewed as in addition to those obtained with the standard statin therapy. In the pooled analysis the LDL reductions were from 130 to 101 mg/dL for the usual dose and from 130 to 75 mg/dL for the high dose, so-called intensive treatment. No significant differences were found between low and high dose treatment for CVD mortality or overall mortality. The analysis involved over 100,000 patient years of observation.
This then is a snapshot of the research behind the statement that for secondary prevention, statins offer benefit in terms of preventing additional adverse coronary events. Critics of the Cholesterol Hypothesis do not appear to dispute this conclusion. Where they part company with the conventional wisdom concerns the use of these results as proof of the Cholesterol Hypothesis, frequently with statements embellished with superlatives. As will be discussed below, the use of high statin doses, presumably for life, raises questions about side effects over and above those already associated with the standard dose protocol.
PRIMARY PREVENTION: THE SPECIAL CASE OF WOMEN OF ALL AGES AND THE
The pooled studies used by Abramson and Wright consisted of five large trials of statins including the three discussed above, which mostly involved primary prevention (average percent primary prevention - 83% of participants, range 56-100%). In the pooled studies, total mortality was not reduced by statins and while the 5-year frequency of total heart attacks and stroke was reduced (relative risk 0.84) the absolute risk reduction was only 1.4%. This is equivalent to needing to treat 71 individuals for 5 years to prevent one event. They also quote the results of the PROSPER randomized controlled trial which involved over 5800 men and women over 69 years of age . In a subset of 3239 men and women in this trial with no evidence of previous vascular disease and viewed at risk because of smoking, hypertension or diabetes, this study found that statins did not reduce total cardiovascular events. When the PROSPER results were stratified just by gender, among women there was no significant benefit from statin treatment and an unspecified number of the total female cohort actually had prior vascular disease. In the interpretation part of the abstract of the PROSPER paper no mention was made of the absence of benefit for primary prevention or for elderly women in general (primary or secondary prevention), but rather, it is simply stated that the statin in question given for 3 years reduced the risk of coronary disease in elderly individuals, thereby omitting an important result. This is in spite of the fact that of the 5804 individuals included in the analysis, about 56% were in the "no previous vascular disease" category, i.e. a significant fraction of the total study population. This data has been in the literature since 2002. Finally, the paper published in 2004 in the Journal of the American Medical Association to which Abramson and Wright make reference found for women without cardiovascular disease, cholesterol lowering with a statin drug did not affect total or coronary heart disease mortality. For fatal heart attacks, revascularization or coronary heart disease events, only one out of nine studies showed significant treatment benefit and this was just for one outcome of many reported in that study. Even for those with known cardiovascular disease, lipid lowering did not affect total mortality. This was a study of studies (meta-analysis) which included six trials involving 11435 women of various ages without cardiovascular disease . Thus the evidence points to the conclusion that in the context of primary prevention for women of all ages and the elderly of either gender, cholesterol lowering is without benefit -- a non- issue.
THE LOWER THE BETTER. WE ALL HAVE ELEVATED LDL
O'Keefe et al also attempt to justify their belief that every one should have an LDL level between 50 and 70 mg/dL by presenting some diagrams of CHD events vs. LDL and showing a linear correlations where CHD events go to zero in this LDL range. However, there are problems with this approach. Let's consider the correlation they obtained based on primary prevention trial data. Three studies were used. One involved only men with very high LDL and TC and one involved only hypertensives with three additional risk factors. The third looked at mostly men with average cholesterol levels. When the CHD event rates are plotted vs. the baseline average LDL and the average LDL achieved after statin treatment, a straight line results going to zero events at an LDL of 55 mg/dL. But these three populations are not comparable and this approach involved no corrections for confounding. The high cholesterol group probably included individuals with FH. And data from only three studies were used. If one wants to examine the correlation between cholesterol and CHD events, this highly limited data set uncorrected for confounding does not appear to be a very good way to do it. And this analysis also ignores the great danger of extrapolating data. Finally, the many results discussed in Part I where no correlation was found among asymptomatic individuals between CAD events and TC (and thus LDL) except for young men argues against the validity of this or the other similar correlations used by O'Keefe et al.
The acceptance and implementation of the notion that only LDL in the range of 50-70 mg/dL is healthy and that if one does not meet this criterion, lipid lowering is in order, would put a significant fraction of the developed world and the rich and well-off elsewhere on statins for life since there is currently no other means of achieving these very low levels. Exercise and diet would for most not accomplish such reductions, given that such lifestyle interventions are already well known to produce only small changes in TC or LDL.
SIDE EFFECTS WITH STATIN THERAPY
Before a drug is approved, drug companies must study adverse side effects. This is generally done with at most several thousand subjects over a fairly short period, a system that is bound to fail. If we had mandatory long-term (say 5-10 years) testing for side effects in a cohort of say 10 or 20 thousand subjects, the introduction of new drugs would decline precipitously. In fact, the industry would probably never allow this to happen. The point is that only the most prevalent side effects manage to surface. After the drug is approved, a mechanism exists for the reporting of adverse side effects, but it is well known that the compliance is negligible with only about 1% of the cases reported. When very serious side effects were just below the threshold of detectability during clinical trials but surfaced when several million prescriptions are written, it is not uncommon that the drug is recalled, although the period of denial can be considerable (e.g. the Vioxx incident). Side effects either ignored or missed in the clinical trials have to kill or disable enough patients for someone to notice. Numerous examples could be quoted. With the statin drugs, it is very easy for a physician to regard side effects as simply manifestations of aging or related to some comorbidity or lifestyle excess. There must also be an element of denial involved since statins are taken by millions worldwide every day, so how can there be any serious problems? It is interesting that in veterinarian medicine both alertness to adverse effects and a willingness to immediately take action appears much greater than in human medicine. Evidence - the very rapid recognition and equally rapid response to the recent contaminated pet food incident.
Comprehensive reviews of the side effects of statin drugs are mostly to be found outside mainstream medical literature and are thus easily dismissed or ignored by the establishment. But some of the voices have considerable credibility. For example, the author of Statin Drugs-- Side Effects and the Misguided War on Cholesterol and Lipitor--Thief of Memory is Dr. Duane Graveline, M.D., a former astronaut, an aerospace medical research scientist, NASA flight surgeon. Another voice is that of Dr. Mary G. Enig, Ph.D., a well-known and respected authority on lipid biochemistry and the author of over 60 publications and presentations. She is the author of Know your Fats: The complete Primer for Understanding the Nutrition of Fats, Oils and Cholesterol.
Graveline's most recent book on Lipitor and memory provides an account of his shocking experiences with what is called transient global amnesia (TGA), a sudden temporary total loss of memory where one does not recognize anything or anybody and fails to have memory of past events going back decades. When his first incident occurred, no one was able identify a cause. After he recovered he reasoned that it might be medication related. He had been put on Lipitor and immediately discontinued it. No more episodes occurred until he resumed Lipitor under pressure from his physician. Then he had a second and more serious episode. This prompted him to set up a website and collect information on statin side effects and in particular TGA. Over several years he has collected enough data to convince himself that TGA is much more common than acknowledged. This is not a trivial matter since there are many occupations where such an episode could prove dangerous to others than the victim, e.g. an airline pilot at the controls during a final approach. In his book on side effects Graveline provides a comprehensive review which should be of interest to anyone taking or contemplating taking statins. His website www.spacedoc.net updates his continuing research and data collection on adverse side effects and in particular what is reported to the government site (Medwatch).
Mary Enig and Sally Fallon have written a review of statin side effects which was published by the Weston A. Price foundation and can be found on its website www.westonaprice.org. They point out what most scientists involved in cholesterol research know, statins not only interfere with cholesterol synthesis but also with a number of other biochemical pathways which generate substances of critical biological importance. The two most important are co-enzyme Q10, a critical cellular micronutrient present in all mitochondria, and a family of compounds call dolichols which in cell biochemistry direct manufactured proteins to their proper targets in response to DNA directives, ensuring that cells respond correctly to genetically programmed instructions. Also, squalene, an intermediate in the reaction chain that yields cholesterol, has anti-cancer properties.
But statins also reduce the synthesis of another compound, mevalonate, which among other things is involved in clotting mechanisms and thus might cause changes that are in a favorable direction. There are other potentially beneficial biochemical actions of statins that are under intense investigation by scientists impressed by the growing evidence that statins act by mechanisms independent of cholesterol lowering. Lipid lowering is also very effective in relieving anxiety about elevated cholesterol levels, and this may have significant health benefits.
But to return to adverse side effects, let it suffice to list them: (a) muscle pain and weakness including potentially fatal rhabdomyolysis; (b) peripheral neuropathy and nerve damage which can be permanent; (c) heart failure thought to be partly due to a deficiency of co-enzyme Q-10, a biochemical that incidentally is used in some countries as a prescription drug to treat heart failure; (d) dizziness and large drops in blood pressure; (e) cancer and the depression of the immune system. Statins have even been suggested for use with transplant patients as an anti-rejection drug; (f) depression linked to low cholesterol levels. This list comes from the review by Enig and Fallon cited above. More details can be found in Graveline's books, which also include some interesting case histories. It is probably safe to say nobody really knows the prevalence of the adverse side effects of this class of drug. This is also not a popular or prestigious area of research, nor one where it is easy to get funding.
In his book on side effects cited above, Graveline presents numerous anecdotal reports where the individuals involved though their problems were connected to statins, but their symptoms were attributed to Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, i.e. (Lou Gehrig's disease (ALS), or multiple sclerosis. This puts the problem in clear perspective. The incidence of such disorders increases with age and there are no widely recognized or accepted studies that directly relate statin use to these symptoms. Thus while physicians would not be surprised to see an increase in patients presenting with symptoms of these neurological disorders, in general they would not make any association with statins. Statins after all, except for what the industry describe as very rare muscle problems, are thought to be safe. The point is, while it may be true that statin users are putting themselves at increased risk of neurological disorders which may mimic the diseases listed above, it is unlikely that mainstream medicine will recognize the potential connection. The association if present may never be established to the satisfaction of those demanding evidence. The studies are too long, too difficult to organize, and too difficult to interpret, given that the incidence of the problems in question is rare, although certainly significant to those who experience the symptoms. And who is going to pay for them? What is really alarming about the anecdotal reports given by Graveline is that in most cases, while symptoms diminished after termination of statin use, in some individuals they did not completely resolve, leaving patients worried that the damage sustained, possibly by statin use, was permanent. No one appears to be seriously studying these issues. In the real world of evidence based medicine, anecdotal reports are easily dismissed. Finally, in this review evidence was presented that cholesterol was not an issue for women or the elderly provided they did not have CHD. Yet there are millions of women of all ages and as well elderly individuals who are on statins and yet to not have CHD. If indeed they do not need statins, then they are unnecessarily putting themselves at risk for serious side effects.
This is not just an issue that cholesterol critics have emphasized. There is a class action lawsuit before the courts in the US claiming damages from a drug company for encouraging the medical profession to prescribe statins to women and the elderly. According to the submission to the court, the case is based on the contention that there is no evidence from relevant studies indicating benefit and there is a risk of harm for the age-gender groups in question.
These then are some of the considerations that come into play when trying to weigh the risks and benefits of statin therapy. If one believes that cholesterol is not an issue for women or for the elderly who do not have CHD, then one side of the scale has nothing on it. For young men, this is an important issue given the large number of individuals needed to treat to prevent one adverse CHD incident.
STATINS FOR CHILDREN ???
Risk factors and high-risk conditions: Male gender, low HDL, high triglycerides, small dense LDL, overweight or obese and other aspects of the metabolic syndrome, hypertension, smoking or exposure to passive smoke, and elevated lipoprotein(a), homocysteine, or c-reactive protein. Finally, there are medical conditions that increase the risk such as diabetes, HIV infection, systemic lupus erythematosus, organ transplantation or surviving childhood cancer and these also count as risk factors.
The authors comment that the evidence base underlying these recommendations including LDL targets is supported only by indirect evidence, evidence extrapolated from studies on adults, studies performed in the context of familial hypercholesterolemia and expert consensus. Furthermore, they caution that direct evidence of an impact of interventions during childhood and adolescence on later cardiovascular morbidity and mortality will likely always be lacking and that drug therapy should only be targeted toward individuals with high-risk lipid abnormalities or high- risk conditions who have not reached the target lipid levels with lifestyle modification.
First, how common are levels of 190 or 160 mg/dL? A recent study looked at averages from data collected between 1988 and 2002 . For the age group from 12 to 20 years, mean LDL values were about 100 mg/dL. For men, the 98th percentile came in at about 155 mg/dL and for women the 95th percentile was about 135 mg/dL. Thus for this age group, LDL > 160 or especially = 190 is rare and appears to truly represent an abnormality. But In the group of children with LDL > than 160 mg/dL, if only two of the above listed risk factors are necessary for triggering drug intervention, then this no doubt expands the eligible group considerably. Second, how successful are dietary interventions in correcting elevated LDL. In a study published in 2001, a conventional intervention involving reductions in total fat, saturated fat and dietary cholesterol over 5-8 years produced a 2.0 mg/dL drop in LDL when comparison was made with a control group. Furthermore, for this group which was initially 8-10 years old, both the intervention and control groups experienced a drop in LDL from about 130 to 110 mg/dL on 5-8 years follow-up . Obviously, a 2 mg/dL decrease in LDL would seem to have little clinical significance, especially if one has an LDL over 160 and measurements in this age group may have little value anyway.
However, there are fundamental questions. We are dealing here with recommendations that are by and large not based on studies relevant to the age group in question nor to the intended long- term use of drug intervention. In a special article for the journal Pediatrics, Belay et al address these and related issues . They make the following points: (a) Randomized clinical trials of statins in adults have been mostly for secondary prevention in older adults, and because even children considered at the highest risk rarely experience a cardiovascular event, the results of secondary prevention trials in adults should be cautiously applied to children; (b) the translation of aggressive treatment targets based on secondary prevention trials from adults to children and adolescents is not justified for primary prevention; (c) primary prevention studies using statins with adults have not demonstrated any reduction in absolute risk for total mortality. They regard this as a crucial aspect since before statins are used for primary prevention in children and adolescents, they consider it critical to demonstrate that total mortality is reduced in later life with childhood statin therapy; (d) the anti-inflammatory benefits of statins on advanced atherosclerotic plaques may not be seen in children whose plaques are at a much different stage of development. They go so far as to suggest that the effect of statins seen in primary prevention relates to the subgroups of individuals who already have unstable plaques; (e) with regard to the safety issue, the AHA position which incidentally seems to downplay side effects, is based on trials with children that have lasted only from 6 months to 2 years and the clinical trials on adolescents and children have been underpowered (too few subjects) to detect infrequent or rare adverse effects. They also point to the problem that the intervention is during cognitive and endocrinologic maturation, skeletal growth, and bone mineral accretion and that there are no studies that directly address other statin safety issues in this age group.
Other problems need to be mentioned. Statins may be associated with central nervous system problems and limb anomalies in about 15% of exposed first-trimester pregnancies . Therefore, statin therapy among female teenagers capable of reproduction may carry a very significant birth defect danger unless contraceptives are successfully employed. Also, girls have lower risk of developing cardiovascular disease than boys, and this must be taken into account in decisions about who to treat. There are also issues associated with breast cancer risk associated with use of oral contraceptives prior to about age 20 (see the recent review on primary prevention of breast cancer in the archives of IHN).
Finally, a study published in 1990 looked at cholesterol levels in children 8 to 18 years of age and then followed them for 20-30 years to see how many as adults developed cholesterol levels that would have merited continued surveillance and intervention . The researchers found that screening for total cholesterol resulted in significant numbers of individuals being incorrectly classified with respect to future cholesterol level elevations. They point out that based on their results, many children with high cholesterol levels have normal levels in young adulthood without intervention.
While the above considerations seem to make it clear that the AHA recommendations are not, as the authors admit, really evidence based and that there are many important issues, it is however almost impossible to implement studies that start with very young children, put half of them on statins, and follow the cohort for 30-40 years to see if the childhood LDL levels and risk factors that would trigger this drug intervention in childhood really lead to cardiovascular problems in much later life which are significantly decreased in the treatment group. Early treatment vs. treatment of adult disease has never been carefully investigated. Thus the bottom line in the case of children deemed at risk appears to be very aggressive lifestyle intervention to correct childhood obesity and poor dietary habits. But the guidelines talk about diets low in cholesterol and saturated fat, and yet the studies they quote found this intervention had almost no effect on LDL levels. Other studies cited in the guidelines paper also were impractical (no meat or dairy products) or produced only small effects and these on children with normal LDL levels. They also are inconsistent in that they reference the AHA pediatric diet strategies which do not mention avoiding cholesterol containing foods and which appears more in tune with reality . To get the diet plus exercise approach to really work will, it would seem, present a severe but obviously highly worthwhile challenge to parents with children who might be targeted for statin therapy.
In addition, guidelines, which severely restrict fat, will in this age group probably invariably result in a large increase in refined carbohydrate intake with an associated increase in triglycerides and HDL, an increase in the risk of insulin resistance and inflammation, and thus an increase in the risk of atherosclerosis. Just what is being targeted for prevention.
Given that (a) the indications for statin use in children are very far from securely evidence based and in fact mostly based on evidence from adult studies on individuals with heart disease; (b) that we are presumably talking about very long-term therapy; (c) that the long-term safety has not and may never be directly established for this age group; and (d) that the optimum age for pharmaceutical intervention has not been established, it would seem that parents need to be very concerned regarding the recommendation to proceed with childhood statin therapy. But it must also be acknowledged that children with a strong family history of premature heart disease who have very high cholesterol levels are a special case for which some of the objections and cautions enumerated above may perhaps assume somewhat less important. But this does not minimize the problem of the absence of relevant evidence of benefit in this age group.
STATIN BENEFITS UNRELATED TO CHOLESTEROL LOWERING
Studies have revealed that statin-mediated improvements in endothelial function (as for example measured by improved blood flow) occur within days in humans, even after a single dose and before any significant effects on lipids . In fact, a recent study found that a non-statin cholesterol lowering drug (ezetimibe) which was effective in lowering LDL levels failed to improve endothelial function whereas equivalent lipid lowering with a statin produced the benefit . These are called pleiotropic functions of a therapy, and at present this is a very active and expanding area of research.
These pleiotropic functions of statin drugs undermine the argument that is the cornerstone of the Cholesterol Hypothesis. This now appears to be gaining some recognition. For example, Brotman et al  state in a recent article that "observing that statins reduce LDL cholesterol levels while reducing cardiovascular mortality does not prove that LDL causes CHD, since statins also affect other cardiovascular risk factors." They continue, "Since statins affect inflammation, endothelial function, oxidative stress, and coagulation, we cannot conclude that LDL cholesterol is atherogenic based on statin studies alone. This requires as convincing mechanistic explanation and an array of consistent evidence supporting it." Also, in an editorial regarding the SPARCL study  which found 80 mg/day of atorvastatin reduced overall incidence of stroke and cardiovascular events, David Kent remarks that  "However, the finding has not settled the controversy [cholesterol and stroke], since a strong correlation between the reduction of cholesterol level and stroke prevention would be expected regardless of the mechanism by which statins decrease risk, i.e. regardless of whether the cholesterol level is the actual mediator of the treatment effect or merely a marker of adequate therapy and adherence."
This review has more or less ignored HDL cholesterol and the evidence that high levels are indeed protective. The subject of HDL is closely tied to triglycerides and to diet. A diet high in carbohydrates, and especially one with lots of refined carbohydrates such as refined starches and sugar, will in many individuals dramatically raise triglyceride levels and significantly lower HDL levels and at the same time increase the risk of developing insulin resistance and systemic inflammation which includes inflammation of arteries. This places one on the road to atherosclerosis, diabetes, obesity and CHD. These adverse blood lipid changes are accompanied by a shift in the LDL particle size in the direction of small, dense LDL particles thought to be the important fraction in the context of inflammation, atherosclerosis and CHD. In fact, high triglycerides and low HDL are considered to be a good surrogate marker for insulin resistance, and insulin resistance is definitely something to be avoided. Nevertheless, current guidelines include recommendations for low-fat diets and in some cases very low-fat diets and many individuals would find it very difficult to make up the calorie deficit with fruit and green vegetables and a minimum of protein, the latter being avoided because of the fat that many protein sources contain. They turn of necessity to refined carbohydrates in large amounts and thereby defeat the purpose of the dietary recommendation, i.e. reducing the risk of CVD, by raising their triglycerides, lowering their HDL and ultimately acquiring insulin resistance, changes which work in exactly the opposite direction from the goals envisioned by the guidelines.
REFERENCES - PART II
REFERENCES - PART III